News from imprimis pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 06, 2018, 16:01 ET Imprimis Pharmaceuticals Announces Second Quarter 2018 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported results for the second quarter 2018. Notable Highlights from the Second Quarter of 2018: ...

Aug 01, 2018, 07:30 ET Imprimis Announces Multi-Center Clinical Trial for Dropless® TriMoxi™ (Triamcinolone Acetonide-Moxifloxacin for injection) Formulation in Canada

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) through its ImprimisRx ophthalmology business today announced its Canadian partner, Advanced Dosage...

Jul 18, 2018, 07:30 ET Imprimis Pharmaceuticals to Present at the Canaccord Genuity 38th Annual Growth Conference on August 9, 2018

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer,...

May 30, 2018, 07:30 ET ImprimisRx's Dropless® Steroid and Antibiotic Intravitreal Injection Featured in the Prestigious Journal of Cataract and Refractive Surgery

Imprimis Pharmaceuticals, Inc.'s (NASDAQ: IMMY) ophthalmology compounding division, ImprimisRx, is pleased to announce the findings from a study...

May 15, 2018, 07:30 ET Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing from Flying L Partners

Surface Pharmaceuticals, Inc., an affiliated company of Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), today announced it has entered into a...

May 15, 2018, 04:01 ET Imprimis Pharmaceuticals Announces First Quarter 2018 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today reported financial results for the first quarter 2018. Notable Highlights: Revenue of $8.9...

Apr 10, 2018, 07:30 ET Imprimis Pharmaceuticals to feature its patent-pending cyclosporine/chondroitin sulfate and patented non-opioid MKO Melt® (midazolam/ketamine/ondansetron) formulations at the upcoming Cataract & Refractive Surgery Medical Meeting

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), and its ophthalmology-focused ImprimisRx division, today announced its participation and related...

Mar 08, 2018, 04:01 ET Imprimis Pharmaceuticals Announces Fourth Quarter 2017 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the fourth...

Mar 07, 2018, 07:30 ET Imprimis Pharmaceuticals to Present at 30th Annual ROTH Conference on March 13, 2018

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that its Chief Executive Officer,...

Mar 06, 2018, 07:30 ET Imprimis Pharmaceuticals Announces Program for Custom Compounded Ophthalmic Formulations

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmic-focused pharmaceutical company, today announced that it has launched a new program to...

Feb 15, 2018, 07:30 ET Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017...

Jan 24, 2018, 07:30 ET Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced that following inspection by the US...

Nov 14, 2017, 15:01 ET Imprimis Pharmaceuticals Announces Third Quarter 2017 Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the third...

Oct 31, 2017, 07:30 ET Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release third quarter 2017...

Oct 24, 2017, 07:30 ET Imprimis Launches Surface Pharmaceuticals Subsidiary

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has filed a Form 8-K with the SEC...

Oct 19, 2017, 07:30 ET Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it is making compounded...

Oct 02, 2017, 07:30 ET Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured its first patent...

Sep 14, 2017, 08:00 ET FDA Curcumin Investigation Supports Imprimis Statement

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), an ophthalmology-focused pharmaceutical company, provided an update regarding the FDA MedWatch Notice...

Sep 11, 2017, 07:30 ET Imprimis Releases Statement Regarding Allergan Lawsuit

Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY), an ophthalmology-focused pharmaceutical company, today responded to a press release issued by Allergan® ...

Aug 10, 2017, 16:01 ET Imprimis Pharmaceuticals Announces Second Quarter 2017 Financial Results

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the second...

Aug 07, 2017, 08:00 ET Imprimis Statement Regarding Curcumin Emulsion FDA MedWatch Notice

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) today released a statement regarding the FDA MedWatch notification issued on August 4, 2017. Mark L....

Jul 31, 2017, 08:00 ET Imprimis Pharmaceuticals to Host its Second Quarter 2017 Financial Report Conference Call and Webcast on August 10, 2017 at 4:15 p.m. EDT

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported it will release second quarter 2017...

Jul 27, 2017, 08:00 ET Imprimis Pharmaceuticals Patent-Pending Dropless and LessDrops Formulations Exceed One Million Patient Eyes Milestone

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced its core patent-pending ophthalmic...

Jul 20, 2017, 08:00 ET Imprimis Pharmaceuticals Announces $16 Million Debt Facility with SWK Holdings

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has entered into a $16 million...

Jun 29, 2017, 08:00 ET Imprimis Pharmaceuticals Sells Pennsylvania Facility and Sinus Assets

Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today announced it has entered into an agreement to...